Fractional CISO for Medical Device Companies: FDA, QMSR, and Cybersecurity
For medical device makers, cybersecurity is not a separate IT concern. It can affect product integrity, manufacturing continuity, sensitive information, and the ability to demonstrate controlled processes. A fractional CISO for medical device companies can help leadership connect security decisions to quality, operations, and regulatory responsibilities without assuming that one security framework or tool solves every problem.
Discuss your priorities in a free IT Strategy Call with Geoff Pope
Why medical device manufacturers face unique cybersecurity requirements
Medical device companies often rely on interconnected systems across product design, quality management, manufacturing, service, and business operations. A security incident in one part of that environment can have consequences beyond lost access to a file. It may interrupt production, affect the availability or integrity of records, or require leaders to assess possible impacts on product and patient safety.
The risk picture can include connected products, engineering workstations, production equipment, cloud services, remote support, suppliers, and business applications. Each organization has a different mix. A device manufacturer with a connected product and a contract manufacturing network has different priorities from a firm whose main exposure is an aging production environment and a set of quality systems.
There is also a governance challenge. Cybersecurity decisions cross departments. IT may operate identity systems and networks, engineering may own product design choices, quality may control procedures and records, and operations may depend on equipment that cannot be updated casually. Leadership needs a way to make tradeoffs visible and assign ownership. A checklist alone does not resolve conflicting needs or set a sensible order of work.
Cybersecurity is also not identical to regulatory compliance. A control may reduce risk, but the company still needs to determine which requirements apply, document its decisions, and maintain processes that work in practice. The FDA's medical device cybersecurity resource discusses FDA's work and coordinated vulnerability disclosure in this area. Manufacturers should use applicable FDA materials and qualified regulatory counsel to interpret obligations for their particular products and operations.
For business leaders, the useful question is not simply, âAre we secure?â It is: âCan we explain our material risks, show who owns them, and demonstrate that our actions protect the business and support safe, reliable operations?â That requires coordination between executive leadership, IT, security, quality, engineering, and operations.
FDA/QMSR and what it requires from your IT and security leadership
FDA requirements and cybersecurity guidance should be considered in the context of the manufacturer's products, systems, and activities. The Quality Management System Regulation (QMSR) applies to finished device manufacturers intending to commercially distribute medical devices. FDA's QMSR overview provides the agency's information about the regulation, and its QMSR frequently asked questions address the inspection process and related questions. Requirements and implementation details should be confirmed against current FDA materials.
QMSR does not mean every company should respond by buying a particular cybersecurity product or copying a generic policy library. IT and security leadership should help the organization understand how technology supports controlled processes, where risks could affect those processes, and how to maintain evidence of decisions and follow-through. The quality function remains essential: security work should fit the organization's quality system, not operate as an undocumented parallel program.
Leadership should clarify the relationship between security governance and quality responsibilities. For example, teams may need agreed procedures for system access, change management, backup and recovery, incident escalation, supplier review, and documentation. The details depend on the company's environment and applicable obligations. The goal is to make ownership and evidence clear, rather than create paperwork disconnected from daily work.
For cybersecurity provisions relating to certain device submissions, including Section 524B, companies should assess applicability to the specific device and submission with appropriate regulatory expertise. A cybersecurity leader can coordinate technical risk work such as threat modeling and a software bill of materials (SBOM) where relevant, while regulatory and quality professionals determine how that work fits the company's obligations and records. The FDA's cybersecurity in medical devices guidance describes FDA recommendations to industry regarding cybersecurity device design, labeling, and premarket documentation.
These areas intersect, but they are not interchangeable. A quality management system does not by itself remove cybersecurity risk, and a security program does not by itself establish regulatory compliance. Coordination helps a manufacturer make informed decisions, document its rationale, and identify where specialized regulatory advice is needed.
Companies looking at leadership options can review this practical guide to Fractional CISO leadership for a broader view of the role. The medical device context adds a need to work effectively with quality and regulatory colleagues, not just IT staff.
What a fractional CISO does for FDA-regulated manufacturers
A Fractional CISO provides senior cybersecurity leadership on a flexible basis. The role is not simply to select tools or write policies. It helps executives set priorities, assign accountability, and bring security decisions into technology and business governance. At a manufacturer, this often means translating technical risk into operational and quality-system considerations that leaders can act on.
Assess and prioritize risk. Build a working view of critical systems, sensitive data, dependencies, likely threat paths, and business consequences. Prioritize actions according to risk and organizational capacity rather than treating every issue as equally urgent.
Set governance and ownership. Clarify who makes decisions and who carries out work across IT, quality, engineering, operations, and leadership. Establish a practical way to review exceptions, risks, and progress.
Connect security to change and product processes. Coordinate with the people responsible for product development, production technology, quality systems, and supplier relationships. Help ensure security questions surface early enough to inform a decision.
Guide incident readiness. Establish clear escalation paths, decision roles, communication steps, and recovery priorities. Practice how relevant leaders would coordinate during a disruption, while tailoring plans to the organization's actual systems.
Oversee third-party and supplier risk. Identify important external dependencies, understand their access or operational role, and use a consistent process to evaluate and monitor material risks.
Explain risk to executives and boards. Present concise updates that connect exposure, business impact, decisions needed, and progress. Make clear what is known, what remains uncertain, and who owns the next step.
That leadership should complement, not displace, internal IT and quality expertise. Internal teams know the environment and keep systems running. A senior security advisor can add structure, executive perspective, and a forward-looking plan, while the organization retains responsibility for decisions and implementation.
Turning Point Advisory provides Fractional CISO services that include security program development, risk assessment, incident response planning, vendor and third-party security management, and compliance-driven security governance. Its medical device industry work addresses FDA QMSR, ISO 13485, 21 CFR Part 11, eQMS, and related technology leadership needs. The right scope still depends on a company's needs and operating context.
How to build a cybersecurity program that satisfies regulators and protects patients
A useful program is a managed cycle, not a one-time assessment. It should reflect the organization's products, systems, risk tolerance, and responsibilities. The sequence below offers a practical starting point, not a substitute for determining applicable legal and regulatory requirements.
Establish scope and accountability. Identify products, sites, business processes, systems, data, and external dependencies that matter to security and continuity. Name executive sponsors and process owners. Include quality, engineering, operations, and IT in the discussion so that the scope reflects real work.
Understand current risk and controls. Review the existing security program, architecture, access practices, incident plans, supplier dependencies, and open remediation items. Ask how critical records and operations would be affected by a loss of availability or integrity. Record assumptions and gaps rather than presenting an incomplete inventory as certainty.
Connect risk to quality and regulatory processes. Work with quality and regulatory colleagues to determine how security activities map to established procedures and documentation. Decide how relevant changes, exceptions, incidents, and corrective actions are escalated and recorded. Confirm interpretations with appropriate specialists where needed.
Choose a small number of prioritized actions. Address high-impact exposures and foundational weaknesses first. Depending on findings, this might include stronger access controls, more reliable backups, better network separation, a defined patching approach, improved supplier oversight, or a tested response process. The actual priorities should come from assessment, not a preselected product list.
Define evidence and measures. Set practical indicators that show whether important controls are operating and whether agreed actions are progressing. Examples include tracking completion of risk actions, response exercises, overdue access reviews, or recovery tests. Choose measures that help management decide; avoid reporting activity counts without explaining risk or impact.
Test, learn, and adjust. Exercise incident response and recovery with relevant teams. Review what worked, what was unclear, and whether the documented process matches actual responsibilities. Update plans as products, systems, suppliers, and threats change.
Leaders can use a simple table to distinguish the purpose of key program work. It is not a compliance checklist; it helps teams ask who owns each activity and what evidence is useful.
Risk assessment. Business question: Which systems or dependencies could materially affect operations or product-related processes? Useful evidence or output: Prioritized risk register, named owners, and documented assumptions
Governance. Business question: Who approves priorities, exceptions, and remediation decisions? Useful evidence or output: Decision rights, escalation paths, and meeting or review records
Incident readiness. Business question: Can the right people coordinate response and recovery under pressure? Useful evidence or output: Response roles, tested procedures, exercise findings, and follow-up actions
Supplier oversight. Business question: Which external parties have important access or operational dependencies? Useful evidence or output: Risk-based reviews, agreed requirements, and tracked issues
Quality-system alignment. Business question: How do relevant security changes and events connect to established quality processes? Useful evidence or output: Approved procedures and records maintained with quality and regulatory input
People and process matter as much as technology. A technically sound control can fail if responsibilities are unclear, exceptions remain open without review, or staff do not know how to escalate a concern. Conversely, a well-defined process needs workable technology and enough capacity to carry it out. An executive sponsor can help teams make those tradeoffs explicit and fund the highest-priority needs.
Manufacturers should also consider continuity. Recovery plans need to reflect which systems and processes are critical, dependencies on suppliers, and realistic recovery expectations. A backup is only useful if it can be restored and the organization knows how to resume important work. Exercise results can reveal gaps that policy documents alone will not show.
Talk through your medical device cybersecurity priorities with Geoff Pope
Choosing a fractional CISO with medical device industry experience
Not every security leader has worked in an environment where cybersecurity, product development, production, and quality processes meet. When evaluating a fractional CISO, ask how the person will learn your systems and work with the people accountable for them. Specific examples of approach are more useful than broad promises or a list of tools.
How will you work with quality and regulatory teams? Look for a collaborative approach that respects their responsibilities and asks how security activities fit existing processes. Be cautious of anyone who treats a technical assessment as proof of compliance.
How do you prioritize risks? Ask how they will connect technical findings to operational consequences, explain uncertainty, and make a sequence of recommendations your team can realistically act on.
How will you handle connected products and manufacturing technology? Ask about the process for understanding product, engineering, operational technology, and IT dependencies. A credible response should start with discovery and collaboration, not assume one architecture fits every manufacturer.
What will the first phase produce? Clarify expected outputs, access to internal staff, decision points, and how progress will be communicated. Agree on scope before assuming a fixed timetable or outcome.
How independent is the advice? Ask whether recommendations are driven by your requirements and risk assessment or by a preferred vendor relationship. You should understand the reasoning behind any proposed investment.
Who will do the work and stay involved? Confirm who leads the engagement, how often executives will meet, and how knowledge will be transferred to the internal team. Continuity and access should be explicit parts of the working arrangement.
Also ask how the advisor distinguishes leadership from implementation. A Fractional CISO can help set direction, advise on controls, and govern a program; internal teams and selected providers may carry out specific technical work. Clear boundaries reduce confusion about accountability and help executives see what decisions or resources are required from them.
Turning Point Advisory describes its approach as vendor-agnostic and founder-led, with Geoffrey Pope directly involved in client engagements. Learn more about its founder and IT leadership experience, or review its industry-focused consulting to see how advisory work is framed across regulated environments.
Frequently Asked Questions
Does every medical device company need a Fractional CISO?
No single model fits every organization. A company may need outside senior security leadership when it lacks executive-level security capacity, faces complex cross-functional risks, or needs an experienced partner to guide an internal team. Scope should follow the company's size, risk, resources, and applicable obligations.
Does having a Fractional CISO make a manufacturer compliant?
No. An advisor can support risk assessment, governance, documentation, and coordination, but the manufacturer remains responsible for its decisions and obligations. Regulatory interpretations should be confirmed with appropriate regulatory or legal professionals.
Can a Fractional CISO replace the IT team or quality leader?
No. The role provides senior cybersecurity leadership and works alongside internal IT, quality, engineering, operations, and regulatory teams. Those teams retain their own responsibilities and provide essential knowledge of the company's processes and systems.
What should leaders expect at the start of an engagement?
Expect discovery and alignment before a detailed action plan: clarify business priorities, understand key systems and stakeholders, assess existing work, and identify decisions that need executive attention. The scope and timing depend on the organization's environment and the information available.
Medical device cybersecurity works best when it is treated as an ongoing leadership responsibility connected to quality, operations, and product risk. Start by making ownership clear, understanding the most important exposures, and agreeing on practical next steps with the people who must carry them out.
